⏳ Fetching live dividend data...
Home › Calculator › ZYXIQ Dividend Calculator 2026
Zynex, Inc. · OTC
Price: $0.06 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ZYXIQ → $634.59M in 10 years · $1,833.85/month
Zynex, Inc. is a medical technology company focused on the development, manufacturing, and marketing of electrotherapy devices. These devices are primarily designed to alleviate both chronic and acute pain, and to facilitate muscle activation and rehabilitation. The company's core product offerings include several electrical stimulation devices: NexWave: A versatile, dual-channel device combining interferential current, Transcutaneous Electrical Nerve Stimulation (TENS), and Neuromuscular Electrical Stimulation (NMES) modalities. It is actively promoted to healthcare professionals by the company's field sales team. NeuroMove: An innovative device integrating electromyography with electrical stimulation technology. InWave: An electrical stimulation product specifically engineered for the treatment of female urinary incontinence. E-Wave and M-Wave: Both are specialized NMES devices. Beyond its proprietary devices, Zynex also supplies private-label accessories essential for electrotherapy, such as electrodes for current delivery to the body and batteries to power its products. Furthermore, the company distributes a range of complementary rehabilitation equipment from other manufacturers, including Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, various braces for knee and wrist rehabilitation, and Dynacomp for cold compression therapy. Zynex is also actively engaged in the development of advanced patient monitoring systems. Its pipeline features the Zynex Fluid Monitoring Systems (CM-1500 and the wireless CM-1600), which are non-invasive devices designed to track relative fluid volume changes in adult patients. Other forthcoming monitoring technologies include the NiCO CO-Oximeter, a laser photoplethysmographic device, and the HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company's diverse product portfolio serves critical medical applications, including pain management and control, rehabilitation for stroke and spinal cord injuries, and sophisticated fluid and pulse oximetry monitoring. Zynex primarily sells its products directly to customers through its dedicated sales force, operating predominantly within the United States. Established in 1996, Zynex, Inc. maintains its corporate headquarters in Englewood, Colorado. However, on December 15, 2025, Zynex, Inc. and its affiliated entities filed for Chapter 11 bankruptcy protection, seeking reorganization in the U.S. Bankruptcy Court for the Southern District of Texas.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ZYXIQ position with:
Real after-tax yield depends on where you live and how you hold ZYXIQ.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3636.36% | 3633.56% | $363,636 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 3090.91% | 3088.11% | $309,091 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2909.09% | 2906.29% | $290,909 / yr |
| 🇬🇧 UK ISA | 0% | 3636.36% | 3633.56% | $363,636 / yr |
| 🇬🇧 UK Taxable | 8.75% | 3318.18% | 3315.38% | $331,818 / yr |
| 🇨🇦 TFSA | 0% | 3636.36% | 3633.56% | $363,636 / yr |
| 🇨🇦 CA Taxable | 25% | 2727.27% | 2724.47% | $272,727 / yr |
| 🇦🇺 Super (pension) | 15% | 3090.91% | 3088.11% | $309,091 / yr |
| 🇦🇺 AU Taxable | 30% | 2545.45% | 2542.65% | $254,545 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2677.27% | 2674.47% | $267,727 / yr |
| 🇫🇷 FR Taxable | 30% | 2545.45% | 2542.65% | $254,545 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ZYXIQ pays quarterly — 4 times per year. Next ex-div: TBD.
How ZYXIQ compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ZYXIQ sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2025-07-27 | 7,500 | — | — | ||
| F-InKind | 2025-07-28 | 3,793 | $2.56 | $9.7K | ||
| A-Award | 2025-06-05 | 5,000 | — | — | ||
| F-InKind | 2025-06-05 | 3,982 | $2.13 | $8.5K | ||
| A-Award | 2025-05-15 | 10,000 | — | — | ||
| A-Award | 2025-05-15 | 10,000 | — | — | ||
| A-Award | 2025-05-15 | 10,000 | — | — | ||
| A-Award | 2025-04-27 | 7,500 | — | — | ||
| F-InKind | 2025-04-28 | 2,716 | $2.25 | $6.1K | ||
| D-Return | 2025-03-13 | 1,700,000 | $2.90 | $4.94M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ZYXIQ dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Zynex, Inc. (ZYXIQ) is currently trading at $0.06, trading near its 52-week low. The current dividend yield is 3636.36% based on an annual payout of $2.00 per share.
Zynex, Inc. (ZYXIQ) is a healthcare stock currently trading at $0.06 with a dividend yield of 3636.36%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, ZYXIQ has grown its dividend at a compound annual rate of 50.0%.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever